Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV003328262 | SCV000864602 | pathogenic | CDH1-related diffuse gastric and lobular breast cancer syndrome | 2023-08-29 | reviewed by expert panel | curation | The c.2430delT (p.Phe810Leufs*6) variant is predicted to result in a premature stop codon that leads to a truncated protein. However, it is located within the nonsense mediated decay resistance region upstream of c.2506G>T (p.Glu836*) (PVS1_Strong). This variant is absent in the gnomAD cohort (PM2_Supporting; http://gnomad.broadinstitute.org). This variant has been reported in at least 4 families meeting HDGC clinical criteria (PS4; PMID 26182300, SCV000261293.4, SCV000218032.4). In summary, this variant meets criteria to be classified as pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PVS1_Strong, PM2_Supporting, PS4. |
Ambry Genetics | RCV000167195 | SCV000218032 | pathogenic | Hereditary cancer-predisposing syndrome | 2024-01-05 | criteria provided, single submitter | clinical testing | The c.2430delT pathogenic mutation, located in coding exon 15 of the CDH1 gene, results from a deletion of one nucleotide at nucleotide position 2430, causing a translational frameshift with a predicted alternate stop codon (p.F810Lfs*6). This alteration was identified in a proband with a family history of gastric cancer who was diagnosed with diffuse gastric cancer at age 45 (Hansford S et al. JAMA Oncol. 2015 Apr;1(1):23-32). In addition, a mutation resulting in the same stop codon (c.2398delC) has been seen in multiple patients and families with diffuse gastric cancer and lobular breast cancer (Kaurah P et al. JAMA. 2007 Jun;297(21):2360-72; Petridis C et al. Br. J. Cancer. 2014 Feb;110(4):1053-7). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation. As such, this alteration is interpreted as a disease-causing mutation. |
Labcorp Genetics |
RCV000204049 | SCV000261293 | pathogenic | Hereditary diffuse gastric adenocarcinoma | 2023-07-25 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupt the cytoplasmic domain of the CDH1 (E-cadherin) protein, including the PIP5K1C and CTNNB1 binding domains (PMID: 22850631, 19268661) which are necessary for E-cadherin function. While functional studies have not been performed to directly test the effect of this variant on CDH1 protein function, this suggests that disruption of this region of the protein is causative of disease. ClinVar contains an entry for this variant (Variation ID: 187464). This premature translational stop signal has been observed in individuals with diffuse gastric cancer and gastric cancer (PMID: 26182300; Invitae). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Phe810Leufs*6) in the CDH1 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 73 amino acid(s) of the CDH1 protein. |
Gene |
RCV000484305 | SCV000567126 | pathogenic | not provided | 2018-04-30 | criteria provided, single submitter | clinical testing | This deletion of one nucleotide in CDH1 is denoted c.2430delT at the cDNA level and p.Phe810LeufsX6 (F810LfsX6) at the protein level. The normal sequence, with the base that is deleted in brackets, is ATTT[delT]ATTG. The deletion causes a frameshift, which changes a Phenylalanine to a Leucine at codon 810, and creates a premature stop codon at position 6 of the new reading frame. This variant has been reported in a family with a diagnosis of Hereditary Diffuse Gastric Cancer (Hansford 2015). We consider this variant to be pathogenic. |
Color Diagnostics, |
RCV000167195 | SCV000903747 | pathogenic | Hereditary cancer-predisposing syndrome | 2020-01-15 | criteria provided, single submitter | clinical testing | This variant deletes 1 nucleotide in exon 15 of the CDH1 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of CDH1 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000204049 | SCV000917127 | likely pathogenic | Hereditary diffuse gastric adenocarcinoma | 2018-02-16 | criteria provided, single submitter | clinical testing | Variant summary: CDH1 c.2430delT (p.Phe810LeufsX6) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant was absent in 120568 control chromosomes. c.2430delT has been reported in the literature in at least one individual affected with Diffuse Gastric Cancer. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic. |
Myriad Genetics, |
RCV000204049 | SCV004043476 | pathogenic | Hereditary diffuse gastric adenocarcinoma | 2023-06-15 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. |
Baylor Genetics | RCV003462236 | SCV004215750 | pathogenic | Familial cancer of breast | 2023-02-22 | criteria provided, single submitter | clinical testing |